Inotrem

Inotrem is a clinical-stage biotech pioneering therapies that modulate the TREM-1 pathway, a key amplifier of inflammatory responses. The company's most advanced asset, nangibotide, is a TREM-1 inhibitor being evaluated in Phase 2b/3 trials for septic shock, a condition with high mortality and no approved targeted therapy. With a platform that could apply to multiple inflammatory conditions, Inotrem is positioning itself in the high-need critical care and immunology markets. The company has secured significant venture funding and strategic partnerships to advance its pipeline.

Platform focused on modulating the TREM-1 (Triggering Receptor Expressed on Myeloid cells-1) pathway using a proprietary peptide inhibitor (nangibotide) to dampen excessive inflammatory responses without causing immunosuppression.

Inotrem is a first-in-class pioneer targeting TREM-1, with no direct competitors sharing its exact mechanism. However, it faces indirect competition from other companies developing anti-inflammatory therapies for sepsis and cytokine storm syndromes (e.g., targeting IL-6, IL-1β). The broader critical care immunology space is attracting increasing interest from large pharma.